Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702504 | 0.87 | NPSR1 (0.47) | NPSR1KCNH2EGFRTSHR | |
| SCHEMBL19904753 | 0.86 | MEN1 (0.46) | ALDH1A1IDO1PNMTTAAR1 | |
| SCHEMBL8958928 | 0.84 | HSD17B10 (0.43) | HSD17B10ALDH1A1NPSR1IDO1SLC6A2 | |
| SCHEMBL8958923 | 0.81 | IDO1 (0.42) | ALDH1A1IDO1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13653125 | 0.81 | PTGS2 (0.51) | TSHR | |
| SCHEMBL16513210 | 0.80 | IDO1 (0.43) | HSD17B10ALDH1A1NPSR1IDO1SLC6A2 | |
| SCHEMBL12212067 | 0.80 | NPSR1 (0.42) | ALDH1A1NPSR1KCNH2EGFRTSHR | |
| SCHEMBL916350 | 0.80 | CCNT1 (0.43) | ALDH1A1NPSR1KCNH2EGFRTSHR | |
| SCHEMBL5250114 | 0.80 | SMN1; SMN2 (0.53) | HSD17B10ALDH1A1NPSR1KCNH2TSHR | |
| SCHEMBL10627650 | 0.79 | TDP1 (0.46) | IDO1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10103401-B2 | Polymer electrolyte composition and polymer electrolyte membrane, polymer electrolyte membrane with catalyst layer, membrane electrode assembly, and polymer electrolyte fuel cell each using the same | TORAY INDUSTRIES, INC. (JP) | 2018-10-16 | — | — | US | disclosed |
| EP-3131145-B1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME | TORAY INDUSTRIES (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-9896479-B2 | Functionalized naphthalene fluorophores | Kay M. Brummond (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896479-B2 | Functionalized naphthalene fluorophores | Kay M. Brummond (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896479-B2 | Functionalized naphthalene fluorophores | Kay M. Brummond (US) | 2018-02-20 | — | — | US | disclosed |
| CN-107709314-A | Efflux pump inhibitor and its therapeutic use | 巴斯利尔药物国际股份公司 | 2018-02-16 | — | — | CN | disclosed |
| US-20170125832-A1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, POLYMER ELECTROLYTE MEMBRANE WITH CATALYST LAYER, MEMBRANE ELECTRODE ASSEMBLY, AND POLYMER ELECTROLYTE FUEL CELL EACH USING THE SAME | TORAY INDUSTRIES, INC. (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3131145-A1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME | Toray Industries, Inc. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-9512174-B2 | Synthesis, structure and use of functionalized naphthalenes | Brummond, Kay M. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512174-B2 | Synthesis, structure and use of functionalized naphthalenes | Brummond, Kay M. (US) | 2016-12-06 | — | — | US | disclosed |
| US-5510351-A | PREGNANE ENZYME INHIBITOR FOR TREATING SKIN DISORDER, BALDNESS, PROSTATIC CANCER | MERCK & CO., INC. (US) | 1996-04-23 | — | — | US | disclosed |
| EP-0646007-A4 | — | — | 1995-04-26 | — | — | EP | disclosed |
| EP-0646007-A1 | NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONES AS 5-g(a)-REDUCTASE INHIBITORS. | MERCK & CO INC (US) | 1995-04-05 | — | — | EP | disclosed |
| EP-0572166-A1 | New 7beta-substituted-4-aza-5a-androstan-3-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | disclosed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993023420-A1 | NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993023050-A1 | NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5242908-A | Of dna and rna | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-09-07 | — | — | US | disclosed |
| CN-1053793-A | Use the disease that benzylphosphonic acid derivatives for treatment is caused by virus | HOECHST AG (DE) | 1991-08-14 | — | — | CN | disclosed |
| EP-0440148-A1 | Use of benzylphosphonic acid derivates for the treatment of viral diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-07 | — | — | EP | disclosed |